抗栓治疗相关脑出血的预后:瑞典卒中登记观察性研究
多变量分析显示,抗血小板与OAC相关脑出血的90天死亡风险均高于非抗栓者,但90天功能依赖风险差异无统计学意义。
要点
- 抗血小板与OAC相关脑出血的90天死亡风险均高于非抗栓相关脑出血。
- OAC相关脑出血的早期(≤24小时)死亡风险升高更明显。
- 90天功能依赖(mRS 3–5)在抗栓与非抗栓组间无显著差异。
核心结论
- 抗血小板相关脑出血和OAC相关脑出血的90天死亡率均高于非抗栓相关脑出血。
- 抗血小板相关脑出血常见且临床结局较差,需进一步研究其临床管理。
研究设计与样本
- 比较OAC相关脑出血(n=2300)、抗血小板相关脑出血(n=3637)与非抗栓相关脑出血(n=7354)。
- 采用单变量和多变量Cox回归分析90天死亡率,并以logistic回归分析90天功能结局(基于自报改良Rankin量表)。
主要发现
- 抗栓治疗患者较无抗栓治疗者更常病前依赖、年龄更大且合并症负担更重。
- 多变量分析中,抗血小板相关脑出血的90天死亡风险比为1.23(95%CI 1.14–1.33),OAC相关脑出血为1.40(95%CI 1.26–1.57),均以非抗栓相关脑出血为参照。
- 早期(≤24小时)死亡风险:OAC相关脑出血HR 1.93(95%CI 1.57–2.38),抗血小板相关脑出血HR 1.32(95%CI 1.13–1.54)。
- 90天功能依赖(mRS 3–5)的多变量比值比:抗血小板1.07(95%CI 0.92–1.24),OAC 0.96(95%CI 0.76–1.22),均无统计学意义。
临床怎么用
- 对使用抗血小板或OAC的患者发生脑出血时,应认识到其90天死亡风险高于非抗栓患者。
- OAC相关脑出血的早期死亡风险尤其突出,提示需关注急性期管理。
局限性
- 本研究为观察性研究,结果可能受混杂因素影响。
- 功能结局基于自报改良Rankin量表。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To date, large studies comparing mortality and functional outcome of intracerebral hemorrhage (ICH) during oral anticoagulant (OAC), antiplatelet, and nonantithrombotic use are few and show discrepant results. METHODS: We used data on 13 291 patients with ICH registered in Riksstroke between 2012 and 2016 to compare 90-day mortality and functional outcome following OAC-related ICH (n=2300), antiplatelet-related ICH (n=3637), and nonantithrombotic ICH (n=7354). Univariable and multivariable Cox regression analyses, with adjustment for relevant confounders, were used to compare 90-day mortality. Early (≤24 hours and 1-7 days) and late (8-90 days) mortality was also studied in subgroup analyses. Univariable and multivariable 90-day functional outcome, based on self-reported modified Rankin Scale, was determined using logistic regression. RESULTS: Patients with antithrombotic treatment were more often prestroke dependent, older, and had a larger comorbidity burden compared with patients without antithrombotic treatment. At 90 days, antiplatelet and OAC were associated with an increased death rate in multivariable analysis (antiplatelet ICH: hazard ratio, 1.23 [95% CI, 1.14-1.33]; OAC ICH: hazard ratio, 1.40 [95% CI, 1.26-1.57]) compared with nonantithrombotic ICH (reference). OAC ICH and antiplatelet ICH were associated with higher risk of early mortality (≤24 hours: OAC ICH: hazard ratio, 1.93 [95% CI, 1.57-2.38]; antiplatelet ICH: hazard ratio, 1.32 [95% CI, 1.13-1.54]). In multivariable analysis, the odds ratios for the association of antiplatelet and OAC treatment on functional dependency (modified Rankin Scale score, 3-5) at 90 days were nonsignificant (antiplatelet: odds ratio, 1.07 [95% CI, 0.92-1.24]; OAC: odds ratio, 0.96 [95% CI, 0.76-1.22]). CONCLUSIONS: In this large observational study, we found that 90-day mortality outcome was worse not only in OAC ICH but also in antiplatelet ICH, compared with patients with nonantithrombotic ICH. Antiplatelet ICH is common and is a serious condition with poor clinical outcome. Further studies are, therefore, warranted in determining the appropriate clinical management of these patients.
引用
- Apostolaki-Hansson T, Ullberg T, Pihlsgård M, et al. Prognosis of Intracerebral Hemorrhage Related to Antithrombotic Use: An Observational Study From the Swedish Stroke Register (Riksstroke). Stroke. 2021. PMID: 33563019. doi:10.1161/STROKEAHA.120.030930
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。